ATE435660T1 - Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen - Google Patents
Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungenInfo
- Publication number
- ATE435660T1 ATE435660T1 AT05850393T AT05850393T ATE435660T1 AT E435660 T1 ATE435660 T1 AT E435660T1 AT 05850393 T AT05850393 T AT 05850393T AT 05850393 T AT05850393 T AT 05850393T AT E435660 T1 ATE435660 T1 AT E435660T1
- Authority
- AT
- Austria
- Prior art keywords
- tumor antigens
- polypeptide consisting
- immunogenic polypeptide
- polypeptide
- optimized
- Prior art date
Links
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 6
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 230000002163 immunogen Effects 0.000 title 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 150000001413 amino acids Chemical group 0.000 abstract 1
- 210000004443 dendritic cell Anatomy 0.000 abstract 1
- 230000005847 immunogenicity Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2005/014212 WO2007073768A1 (en) | 2005-12-23 | 2005-12-23 | Immunogenic polypeptide composed of tumor antigen-derived optimized cryptic peptides, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE435660T1 true ATE435660T1 (de) | 2009-07-15 |
Family
ID=36000393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05850393T ATE435660T1 (de) | 2005-12-23 | 2005-12-23 | Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7973128B2 (de) |
| EP (1) | EP1962889B1 (de) |
| JP (1) | JP4929290B2 (de) |
| CN (1) | CN101370513B (de) |
| AT (1) | ATE435660T1 (de) |
| CA (1) | CA2634480C (de) |
| DE (1) | DE602005015368D1 (de) |
| DK (1) | DK1962889T3 (de) |
| ES (1) | ES2330658T3 (de) |
| PL (1) | PL1962889T3 (de) |
| PT (1) | PT1962889E (de) |
| WO (1) | WO2007073768A1 (de) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010115229A1 (en) * | 2009-04-09 | 2010-10-14 | The University Of Melbourne | Immunogenic composition and uses thereof |
| CN102153658A (zh) * | 2011-01-19 | 2011-08-17 | 上海科医联创生物科技有限公司 | 肿瘤抗原、dc肿瘤疫苗及其制备方法 |
| EP2886127A1 (de) | 2013-12-18 | 2015-06-24 | Vaxon Biotech | Verfahren zur Emulgierung eines Triepitoppeptids mit Montanid und Kits zu seiner Durchführung |
| EP2977059A1 (de) * | 2014-07-22 | 2016-01-27 | Vaxon Biotech | Immunogenes Polypeptid aus HLA-B7-beschränkten, tumorantigenabgeleiteten, optimierten kryptischen Peptiden und Verwendungen davon |
| CN104926944B (zh) * | 2015-05-22 | 2018-04-13 | 北京康爱瑞浩生物科技股份有限公司空港分公司 | 多靶点复合抗原负载cd8+细胞毒性t淋巴细胞的制备方法及其用途 |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001041787A1 (en) * | 1999-12-10 | 2001-06-14 | Epimmune Inc. | INDUCING CELLULAR IMMUNE RESPONSES TO HER2/neu USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS |
| CA2408328C (en) | 2000-05-10 | 2012-04-17 | Aventis Pasteur Limited | Immunogenic polypeptides encoded by mage minigenes and uses thereof |
| FR2812087B1 (fr) * | 2000-07-21 | 2007-05-11 | Inst Nat Sante Rech Med | Procede de criblage de peptides utilisables en immunotherapie |
-
2005
- 2005-12-23 EP EP05850393A patent/EP1962889B1/de not_active Expired - Lifetime
- 2005-12-23 JP JP2008546143A patent/JP4929290B2/ja not_active Expired - Lifetime
- 2005-12-23 CN CN2005800525070A patent/CN101370513B/zh not_active Expired - Lifetime
- 2005-12-23 ES ES05850393T patent/ES2330658T3/es not_active Expired - Lifetime
- 2005-12-23 US US12/158,736 patent/US7973128B2/en active Active
- 2005-12-23 PL PL05850393T patent/PL1962889T3/pl unknown
- 2005-12-23 CA CA2634480A patent/CA2634480C/en not_active Expired - Lifetime
- 2005-12-23 PT PT05850393T patent/PT1962889E/pt unknown
- 2005-12-23 AT AT05850393T patent/ATE435660T1/de active
- 2005-12-23 DE DE602005015368T patent/DE602005015368D1/de not_active Expired - Lifetime
- 2005-12-23 DK DK05850393T patent/DK1962889T3/da active
- 2005-12-23 WO PCT/EP2005/014212 patent/WO2007073768A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| EP1962889B1 (de) | 2009-07-08 |
| DK1962889T3 (da) | 2009-11-02 |
| US20090130133A1 (en) | 2009-05-21 |
| CN101370513A (zh) | 2009-02-18 |
| JP4929290B2 (ja) | 2012-05-09 |
| CA2634480A1 (en) | 2007-07-05 |
| CN101370513B (zh) | 2013-04-03 |
| US7973128B2 (en) | 2011-07-05 |
| WO2007073768A1 (en) | 2007-07-05 |
| PL1962889T3 (pl) | 2010-03-31 |
| CA2634480C (en) | 2013-10-15 |
| DE602005015368D1 (de) | 2009-08-20 |
| EP1962889A1 (de) | 2008-09-03 |
| PT1962889E (pt) | 2009-10-14 |
| JP2009520472A (ja) | 2009-05-28 |
| ES2330658T3 (es) | 2009-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2121731E (pt) | Vacinas peptídicas para cancros que expressam antigénios associados a tumores | |
| JP2012501959A5 (de) | ||
| JP2014507146A5 (de) | ||
| DK1922335T3 (da) | Tumorassocierede peptider, der bindes promiskuøst til Humant Leukocyt-Antigen (HLA) klasse II molekyler | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| JP2008543314A5 (de) | ||
| EP2562183A8 (de) | Neuartige immunogenetische Epitope zur Immuntherapie | |
| EP1548032A4 (de) | Kdr-peptide und diese enthaltende impfstoffe | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| NZ598605A (en) | Vaccine against african horse sickness virus | |
| CA2408328A1 (en) | Immunogenic polypeptides encoded by mage minigenes and uses thereof | |
| JP2007516696A5 (de) | ||
| MX2009007261A (es) | Vacuna de peptido foxp3. | |
| ATE435660T1 (de) | Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen | |
| NZ594268A (en) | Grass peptides for vaccine | |
| TW201008576A (en) | New fusion proteins and their use for the preparation of vaccines against hepatitis C | |
| PH12018502430A1 (en) | Vaccines | |
| MX2010010025A (es) | Proteina de fusion con direccionamiento de antigenos vacunales a celulas presentadoras de antigeno y sus aplicaciones. | |
| AR053372A1 (es) | Proteinas inmunologicas de lawsonia intracellularis | |
| UA102274C2 (ru) | Эпитопный пептид rab6kifl/kif20a и вакцины, которые его содержат | |
| WO2005076975A3 (en) | Complexed polypeptide and adjuvant for improved vaccines | |
| PT2095822E (pt) | Péptidos de epítopo derivados de receptor de factor de crescimento endotelial vascular 1 e vacinas contendo estes péptidos | |
| RU2021112253A (ru) | Вирусоподобные частицы cmv, модифицированные путем слияния | |
| WO2009149094A3 (en) | Cytotoxic t cell defined egfr peptide and an optimized derivative peptide | |
| CY1114720T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1962889 Country of ref document: EP |